Bryan Badik, MD
Family Medicine · Perrysburg, OHNPI 1669405213
Payments from drug & device makers
Across 258 payments — averaging $13.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$773
- Pfizer$376
- AbbVie$322
- Merck$298
- AstraZeneca$226
- Johnson & Johnson$194
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,39098%
- Education$471%
- Gifts$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 65 | $773 |
| Pfizer | 34 | $376 |
| AbbVie(2 entities) | 21 | $322 |
| Merck | 23 | $298 |
| AstraZeneca | 13 | $226 |
| Johnson & Johnson | 13 | $194 |
| Amgen | 18 | $178 |
| Amarin Pharma, Inc. | 11 | $153 |
| Boehringer Ingelheim | 6 | $118 |
| Kowa Pharmaceuticals America, Inc. | 4 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $89 |
| Teva Pharmaceuticals USA, Inc. | 6 | $81 |
| Novartis | 5 | $75 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $71 |
| Bayer | 4 | $57 |
| Lilly USA, LLC | 3 | $44 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| GSK | 2 | $26 |
| The Binding Site Inc. | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Abbott | 1 | $19 |
| Cordis US CORP. | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Bausch Health US, LLC | 1 | $14 |
| Neos Therapeutics, LP | 1 | $14 |
| Shire North American Group Inc | 1 | $12 |
| Eisai Inc. | 1 | $12 |
How this compares
$3,462 in reported general payments places this provider in the 80th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 140 | $156,596 |
| AplenzinBupropion Hbr | 24 | $116,684 |
| FarxigaDapagliflozin Propanediol | 100 | $80,676 |
| JanuviaSitagliptin Phosphate | 66 | $72,940 |
| MounjaroTirzepatide | 41 | $42,422 |
| XareltoRivaroxaban | 60 | $40,301 |
| EliquisApixaban | 46 | $34,337 |
| InvokanaCanagliflozin | 20 | $24,825 |
| JardianceEmpagliflozin | 16 | $24,194 |
| RybelsusSemaglutide | 19 | $21,557 |
| TradjentaLinagliptin | 20 | $17,322 |
| Spiriva RespimatTiotropium Bromide | 15 | $11,552 |
| MyrbetriqMirabegron | 13 | $10,704 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $8,401 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 244 | $7,942 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $773 | $178,153159 claims |
| Bausch Health US, LLCAplenzin | $14 | $116,68424 claims |
| AstraZenecaFarxiga | $226 | $80,676100 claims |
| MerckJanuvia | $298 | $72,94066 claims |
| Johnson & JohnsonXarelto, Invokana | $194 | $65,12580 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $118 | $53,06751 claims |
| PfizerEliquis, Paxlovid, Prempro | $376 | $44,48686 claims |
| Lilly USA, LLCMounjaro | $44 | $42,42241 claims |
| NovartisEntresto | $75 | $7,86512 claims |
| GSKAnoro Ellipta | $26 | $7,41311 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $15 | $2,34912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Perrysburg
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.